T24-luc Orthotopic Mouse Model Service for Bladder Cancer

The T24-luc orthotopic mouse model merges the well-characterized molecular landscape of human bladder cancer with the power of firefly luciferase reporter tracking, enabling investigators to visualize tumor engraftment, monitor invasive progression, and quantify therapeutic responses in real time within an anatomically faithful urothelial microenvironment. At Alfa Cytology, we engineer and validate this human-derived, optically traceable orthotopic system with rigorous quality controls, delivering a preclinical platform where every photon flux measurement translates into actionable pharmacodynamic insight for your bladder cancer drug development pipeline.

Overview of T24-luc Orthotopic Mouse Model for Bladder Cancer

T24-luc is a genetically modified derivative of the parental T24 human bladder transitional cell carcinoma line, engineered to stably express firefly luciferase through lentiviral transduction. The parental T24 line—originally isolated in 1973 from a Grade 3 invasive bladder tumor in an 81-year-old female patient—carries hallmark oncogenic driver mutations including an activating HRAS alteration (G12V), a TP53 missense mutation, and a TERT promoter mutation, placing it within the genomically stable, basal/squamous-like molecular subgroup of muscle-invasive bladder cancer. Integration of the luciferase reporter does not alter the fundamental epithelial morphology, proliferative kinetics, or tumorigenic potential of the parental line, yet it introduces a powerful optical dimension: following systemic administration of D-luciferin substrate, luciferase-expressing tumor cells emit photons that can be captured non-invasively through the abdominal wall using an in vivo imaging system (IVIS), yielding quantitative, longitudinal data on tumor burden without the need for serial sacrifice.

Fig 1. IHC staining images of the bladder tumor tissue in mice and analyses. (Kalniņa Z, et al., 2025)

When implanted orthotopically into the bladder wall of immunodeficient hosts—typically athymic nude mice following mucosal preconditioning—T24-luc cells reconstitute the layered architecture of human urothelial carcinoma, progressing from superficial mucosal attachment through lamina propria infiltration to muscularis propria invasion. The bioluminescence signal, though modest immediately after instillation, increases markedly over the ensuing weeks and correlates with histopathological tumor volume, enabling sensitive detection of early engraftment and subtle treatment-induced changes that might be missed by caliper-based or gravimetric endpoints alone. This optical traceability makes the T24-luc model particularly suited for evaluating intravesical agents, systemic chemotherapeutics, and molecularly targeted compounds, while simultaneously reducing animal usage through non-invasive longitudinal monitoring.

Cell Line Information: T24-luc

T24-luc represents a luciferase-reporter derivative of the T24 human bladder cancer cell line, generated through stable lentiviral transfection of a firefly luciferase gene construct. The resulting cell population constitutively expresses luciferase under a strong promoter, enabling quantitative bioluminescent detection both in vitro and in vivo. In vitro validation confirms a linear relationship between cell number and photon emission, with coefficients of determination typically exceeding 0.95, establishing bioluminescence as a reliable proxy for viable tumor cell mass. The line retains the full genetic and phenotypic profile of the parental T24 cells while adding a non-invasive optical readout dimension that transforms the orthotopic model from a static endpoint system into a dynamic, longitudinal investigative tool.

Our Services

Alfa Cytology provides a fully integrated T24-luc orthotopic model service that spans lentiviral reporter validation, authenticated cell banking, optimized mucosal preconditioning, surgical implantation, serial IVIS bioluminescence imaging, and comprehensive terminal histopathology. Our preclinical team calibrates every parameter—from cell inoculum density to imaging acquisition settings—to ensure robust signal-to-noise ratios and reproducible tumor kinetics, generating longitudinal datasets that empower data-driven decisions throughout your compound's preclinical development journey.

Workflow of T24-luc Orthotopic Mouse Model Construction

Construction of the T24-luc orthotopic bladder cancer model at Alfa Cytology integrates stringent cell quality assurance, refined transurethral surgical techniques, and systematic bioluminescence imaging protocols. The workflow is designed to maximize tumor engraftment rates while preserving the optical traceability that distinguishes this model from conventional xenograft systems. Each stage is documented with batch records, imaging timestamps, and health monitoring logs to ensure full traceability and regulatory compliance.

1. Cell Line Authentication and Luciferase Validation: T24-luc cells are expanded from authenticated, mycoplasma-negative master cell banks under appropriate biosafety containment. Prior to implantation, STR profiling confirms identity, while an in vitro D-luciferin assay validates constitutive luciferase expression and establishes the linearity of photon output across the intended cell number range.
2. Animal Selection and Acclimation: Female athymic nude mice (Balb/c nu/nu), 6–8 weeks of age, are procured from certified vendors and acclimated for a minimum of 5–7 days under SPF housing. Baseline body weights are recorded, and animals are randomized into experimental cohorts using weight-based stratification prior to tumor cell instillation.
3. Bladder Mucosal Preconditioning: The urothelial barrier is disrupted to enhance tumor cell adhesion. Under anesthesia, 50 µl of 0.1% poly-L-lysine or 0.25% trypsin is instilled via a 25-gauge catheter and allowed to dwell for 15 minutes, after which the bladder is manually emptied. This preconditioning step is critical for achieving consistent engraftment in human xenograft models.
4. Orthotopic T24-luc Cell Instillation: A single-cell suspension of 3.0 × 10⁶ T24-luc cells in 50 µl of serum-free medium is slowly instilled into the emptied bladder lumen through the indwelling catheter. A microvascular clamp is applied around the urethral meatus to prevent leakage, and the inoculum is retained for 1.5 hours while the animal remains under continuous anesthesia with physiological monitoring.
5. Post-Procedure Recovery and Monitoring: Following clamp removal and confirmation of spontaneous voiding, mice are transferred to a heated recovery chamber. Perioperative analgesia is administered per IACUC guidelines. Daily health assessments monitor body weight, hydration, urination patterns, and signs of urinary obstruction or systemic distress, with predefined humane endpoints governing euthanasia decisions.
6. Baseline Bioluminescence Imaging: Initial IVIS imaging is performed 3–5 days post-implantation to confirm tumor cell engraftment. Mice receive an intraperitoneal injection of D-luciferin (150 mg/kg in PBS), and after a 15-minute substrate distribution period, bioluminescence is acquired in the supine position using standardized acquisition parameters. Photon flux is quantified from a region of interest over the lower abdomen.
7. Longitudinal Tumor Monitoring: Tumor growth is tracked non-invasively twice weekly via serial IVIS imaging. The logarithmic increase in photon flux over time provides a sensitive, quantitative measure of tumor burden and growth kinetics. Animals are stratified into treatment arms once tumors achieve a predefined photon flux threshold, ensuring uniform baseline burdens across cohorts.
8. Therapeutic Intervention and Response Assessment: Test compounds are administered according to the investigational protocol—via intravesical instillation, intraperitoneal injection, intravenous infusion, or oral gavage. Treatment response is evaluated through changes in bioluminescence signal trajectory relative to vehicle controls, with imaging schedules synchronized to dosing regimens for optimal pharmacodynamic resolution.
9. Endpoint Analysis and Histopathological Correlation: At study termination, mice are humanely euthanized and subjected to necropsy. Ex vivo bioluminescence imaging of excised bladders and distant organs detects metastatic dissemination with high sensitivity. Bladders are weighed, fixed, and processed for H&E staining to evaluate tumor grade, invasion depth, and muscle layer involvement, with bioluminescence data correlated against histopathological findings for comprehensive endpoint characterization.

Fig 2. T24-luc Orthotopic Mouse Model construction workflow.

Case Study-T24-luc Orthotopic Mouse Model Development

In a representative preclinical engagement, T24-luc cells were orthotopically implanted into immunodeficient mice following poly-L-lysine mucosal preconditioning. Serial IVIS imaging confirmed successful engraftment within the first week, with bioluminescence signal intensifying progressively over the subsequent monitoring period. Upon reaching a predetermined photon flux threshold, animals were randomized into vehicle control and treatment cohorts receiving an investigational therapeutic agent. Longitudinal imaging captured divergent growth trajectories between groups, with the treatment arm exhibiting attenuated signal accumulation compared to controls. Terminal analysis correlated the optical data with histopathological findings, revealing differences in tumor burden, depth of muscularis invasion, and the presence of locoregional lymph node involvement. These preclinical observations furnished quantitative evidence of target engagement and antitumor activity, supporting the compound's advancement into subsequent development stages. All work was conducted exclusively within preclinical parameters under approved animal use protocols.

Why Choose Alfa Cytology?

Partnering with Alfa Cytology for your T24-luc orthotopic bladder cancer program means accessing a preclinical infrastructure purpose-built for optically traceable human xenograft research. Our capabilities bridge advanced imaging technology, rigorous cell line stewardship, and flexible study design to deliver datasets that are both scientifically robust and operationally efficient.

• Validated T24-luc cell stocks with confirmed lentiviral integration stability, constitutive luciferase expression, and linear photon output across the physiologically relevant cell number range.
• Optimized orthotopic implantation protocols incorporating mucosal preconditioning and refined transurethral techniques that maximize engraftment consistency in immunodeficient hosts.
• State-of-the-art IVIS imaging core with standardized acquisition protocols, automated region-of-interest quantification, and real-time data visualization for immediate pharmacodynamic interpretation.
• Non-invasive longitudinal monitoring that reduces animal usage while capturing tumor growth kinetics, treatment response dynamics, and early metastatic events with superior temporal resolution.
• Integrated ex vivo bioluminescence imaging of harvested organs for sensitive detection of micrometastatic lesions that may be occult on standard histopathological sectioning alone.
• Comprehensive endpoint suite encompassing digital histopathology, immunohistochemistry, and molecular profiling, with bioluminescence data correlated against tissue-based findings for multidimensional response characterization.
• Agile project management with dedicated study directors, milestone-driven reporting, and regulatory-compliant documentation packages tailored to IND-enabling and peer-reviewed publication requirements.

Contact Us

Whether your research demands real-time visualization of human bladder tumor progression, quantitative assessment of intravesical drug efficacy, or sensitive detection of micrometastatic spread, we invite you to reach out to us to explore how the T24-luc orthotopic model can accelerate your preclinical program. Our scientific team is ready to customize a study design aligned with your therapeutic mechanism, imaging requirements, and development milestones. Contact us today for a detailed proposal and project timeline.

For research use only. Not intended for any clinical use.